VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Drilon on Entrectinib in Patients With ROS1-Positive NSCLC

Alexander Drilon, MD
Published: Tuesday, Oct 17, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non–small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

ROS1 arrangements occur in about 1% to 2% of lung cancers and are highly actionable drivers, Drilon explains. Moreover, entrectinib is a multikinase inhibitor with activity against ROS1, ALK, and NTRK. Data from a pooled phase I/II experience show that, in patients with ROS1-positive NSCLC, by investigator assessment, the objective response rate was 78.1% with entrectinib, and the median progression-free survival was 29.6 months.

These are similar data to what is seen with crizotinib; however, updated data from the meeting show that there may be better central nervous system efficacy with entrectinib. Additionally, preclinical data show that entrectinib is a more potent inhibitor than crizotinib. 


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non–small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

ROS1 arrangements occur in about 1% to 2% of lung cancers and are highly actionable drivers, Drilon explains. Moreover, entrectinib is a multikinase inhibitor with activity against ROS1, ALK, and NTRK. Data from a pooled phase I/II experience show that, in patients with ROS1-positive NSCLC, by investigator assessment, the objective response rate was 78.1% with entrectinib, and the median progression-free survival was 29.6 months.

These are similar data to what is seen with crizotinib; however, updated data from the meeting show that there may be better central nervous system efficacy with entrectinib. Additionally, preclinical data show that entrectinib is a more potent inhibitor than crizotinib. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x